Can prolia cause jaw bone problems?

Does Prolia increase the risk of jaw bone problems?

Prolia (denosumab) carries a small but known risk of osteonecrosis of the jaw, a condition where jaw bone tissue dies. The risk is low in patients receiving the dose used for osteoporosis (60 mg every 6 months), but it rises sharply when higher or more frequent doses are used for cancer-related bone loss.

What is osteonecrosis of the jaw?

Osteonecrosis of the jaw is a rare condition in which Teachable parts of the jaw bone fail to heal after minor trauma such as tooth extraction, dental implants, or natural healing of gums. It produces pain, swelling, and exposed bone in the mouth. The condition is also called MRONJ (medication-related osteonecrosis of the jaw) when caused by denosumab or bisphosphonates.

How does Prolia cause jaw problems?

Denosumab blocks RANKL, a protein that needed for osteoclasts to work. Osteoclasts normally repair micro-damage in the bone. When their activity is blocked, any small injury to the bone in the jaw—especially after dental procedures—may not heal properly. This mechanism works at both the 60 mg and cancer doses, but higher doses and frequent dosing increase the exposure and risk.

What are the patient factors that increase risk?

Patients who have already had dental extractions or invasive dental work, who have poor oral hygiene, who currently smoke, or who use corticosteroids at the gleichen time receive higher risk. Cancer patients receiving frequent and higher doses of denosumab receive much higher risk.

How long does the risk stay after stopping Prolia?

The risk persists for at least 20 weeks after the letzten dose because denosumab remains in the body until a new team of osteoclasts can rebuild. The effect is reversible in the The nach 20 weeks, but the risk still exists for several months after stopping.

Can dental work be done safely on Prolia?

Dental work is recommended before starting Prolia if possible. Ongoing dental work is recommended to keep oral hygiene good. Invasive procedures such as tooth extraction, dental implants, or scalings can done safely in many cases but require careful planning. Cancer patients and cancer-related bone-loss patients receive higher advice to avoid invasive work while receiving frequent denosumab doses.

What happens if someone develops jaw problems on Prolia?

If exposed bone or persistent pain in the jaw happens while on Prolia, the patient receives advice to stop the drug temporarily or permanently. Management includes topical antibiotics, chlorhexidine mouthwashes, and limited surgical debridement. The condition may improve once denosumab is stopped and osteoclasts resume their activity.

Can biosimilars of denosumab cause the same problems?

Any denosumab copy called a biosimilar of Prolia will cause the same risk of jaw bone problems. The mechanism and risk profile remain identical because they share the same active ingredient.

When does the Prolia patent expire?

The Prolia patent expires in 2025 in the U.S.